In process assessment of critical process parameters impacting CAR T-cell potency, metabolic fitness and phenotype

Thursday, January 9 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST

Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a promising therapeutic approach for several cancers. Despite the growing interest, the widespread use of CAR T-cell therapies has been restricted due to their high cost and the challenges that arise when compared with traditional methods for manufacturing and product QC. Developing sensitive and reliable analytics to characterize CAR-T products' critical quality attributes (CQAs) and tailoring the cell expansion process to achieve these CQAs provides tools for a more consistent manufacturing process.

Join Dr. Laurissa Ouaguia, Scientist, Reagents and Application Development, Agilent Technologies, as she discusses Agilent’s portfolio of cell analysis tools. She will also demonstrate how they can be applied during the production of CAR T-cells using the functionally closed and automated Lonza Cocoon® Platform for cell manufacturing. This approach provides a deeper understanding of the immune phenotype, metabolic fitness, and cytotoxic function of the CAR T-cells throughout the production, allowing for more informed process development.

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.

Webinar details

• Cost: Free to attend
• Location: Online
• Duration: 60 minutes

Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.